Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2020

01-05-2020 | Prostate Cancer | Review Article

Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review

Authors: Kim Edmunds, Haitham Tuffaha, Daniel A Galvão, Paul Scuffham, Robert U Newton

Published in: Supportive Care in Cancer | Issue 5/2020

Login to get access

Abstract

Purpose

Androgen deprivation therapy (ADT) has broad application in the treatment of prostate cancer (PC) and is associated with numerous, debilitating adverse effects. Increasing use of ADT for PC, longer timeframe for treatment (increased uptake of PSA testing and earlier diagnosis), as well as improved survival and an ageing population, means patients can live for a considerable period of time on or after ADT, experiencing these adverse effects. A number of systematic reviews of adverse effects of ADT for PC exist; however, no single systematic review has previously examined the evidence for all adverse effects, including newer forms of ADT.

Methods

A systematic review of existing systematic reviews of ADT for PC was conducted (2010–February 2019), as per Cochrane guidelines, to identify the highest level of risk/incidence evidence available, supplemented by evidence drawn from individual studies where no systematic review existed.

Results

Incidence data was generated for 19 adverse effect subgroups, classified according to the common terminology criteria for adverse events (CTCAE).

Conclusion

Incidence of adverse effects provides valuable information for future burden of disease studies. This information can better guide clinical management to reduce symptoms for patients and assist patients to make more informed decisions about their treatment, potentially improving disease outcomes. It also highlights the importance of supportive care for PC patients receiving ADT and their carers. For analysts conducting economic evaluations, the inclusion of adverse effects in PC decision analytic models can provide more comprehensive and accurate information for decision makers.
Appendix
Available only for authorised users
Literature
1.
Kumar S, Shelley M, Harrison C, Coles B (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. The Cochrane Collaboration [Internet] (4):1–71
2.
Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD (2009) Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 35(7):540–546PubMedCrossRef
3.
4.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate cancer. https://​www.​nccn.​org/​:​ NCCN; 2018. Accessed 15 April 2019
5.
6.
Australian Institute of Health and Welfare (AIHW). Prostate cancer in Australia. Canberra: AIHW; 2013
7.
Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M (2015) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68(3):386–396PubMedCrossRef
8.
Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M (2015) Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One 10(3):e0117344PubMedPubMedCentralCrossRef
9.
Fagerlund A, Cormio L, Palangi L, Lewin R, Di Pompeo FS, Elander A et al (2015) Gynecomastia in patients with prostate cancer: A systematic review. PLoS ONE 10(8)PubMedPubMedCentralCrossRef
10.
Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S (2018) Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 21(4):451–460PubMedCrossRef
11.
Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4(2):128–139PubMedCrossRef
12.
Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, Cui C, Xu T, Yu W, Jin J (2016) A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis 19(4):333–339PubMedCrossRef
13.
Kim D, Lee J, Kim K, H N, Kim J, Hah Y et al (2019) Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis. J Clin Med 8(113)PubMedCentralCrossRef
14.
Kunath F, Grobe HR, Rucker G, Motschall E, Antes G, Dahm P et al (2015) Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU Int 116(1):30–36PubMedCrossRef
15.
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E et al (2015) Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncology 1(9):1261–1269PubMedCrossRef
16.
McGinty HL, Phillips KM, Jim HSL, Cessna JM, Asvat Y, Cases MG, Small BJ, Jacobsen PB (2014) Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer 22(8):2271–2280PubMedPubMedCentralCrossRef
17.
Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y et al (2016) Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16:180PubMedPubMedCentralCrossRef
18.
Nead K, Boldbaatar N, Yang D, Sinha S, Nguyen P (2018) Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis. J Urol 114:155–162CrossRef
19.
Nead KT, Sinha S, Nguyen PL (2017) Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20(3):259–264PubMedCrossRef
20.
Nead KT, Sinha S, Yang DD, Nguyen PL (2017) Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urologic Oncology 35(11):664.e1–664.e9CrossRef
21.
Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 306(21):2359–2366PubMedCrossRef
22.
Roviello G, Sigala S, Danesi R, Re MD, Bonetta A, Cappelletti MR et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 101:12–20PubMedCrossRef
23.
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88–101PubMedPubMedCentralCrossRef
24.
Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E (2016) Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine. 95(24):e3873PubMedPubMedCentralCrossRef
25.
Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M et al (2016) A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine. 95(27):e3845PubMedPubMedCentralCrossRef
26.
Sun M, Cole A, Hanna N, Mucci L, Berry D, Basaria S, Ahern DK, Kibel AS, Choueiri TK, Trinh QD (2018) Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol 199:1417–1425PubMedCrossRef
27.
Wang H, Sun X, Zhao L, Chen X, Zhao J (2016) Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis. Journal of Diabetes Investigation 7(4):629–636PubMedPubMedCentralCrossRef
28.
Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 9(9):e107516PubMedPubMedCentralCrossRef
29.
Zhu J, Liao R, Su C, Liang D, Wu J, Qiu K, Li J (2018) Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert Rev Anticancer Ther 18(2):193–198PubMedCrossRef
30.
31.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Bmj. 339:b2700PubMedPubMedCentralCrossRef
32.
National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: Services UDoHaH, editor.: US Government; 2017
33.
34.
35.
Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj. 358
36.
Higgins J, Sterne J, Savović J, Page M, Hróbjartsson A, Boutron I et al (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10
37.
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Ottawa: The Ottawa Hospital Research Institute; 2019
38.
Schunemann H, Cuello C, Akl E, Mustafa R, Meerpohl J, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence 2018
39.
Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS et al (2014) Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis 17(4):338–342PubMedPubMedCentralCrossRef
40.
Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800–805PubMedCrossRef
41.
Greenspan SL, Nelson JB, Trump DL, Resnick NM, Miller M (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146(6):416–424PubMedCrossRef
42.
Ng HS, Koczwara B, Roder D, Vitry A (2018) Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis 21(3):403–410PubMedCrossRef
43.
Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 111(5):745–752PubMedPubMedCentralCrossRef
44.
Wallis C, Mahar A, Satkunasivam R, Hershorn S, Kodama R, Lee Y et al (2016) Cardiovascular and skeletal-related events folowing localised prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. J Urol 97:145–152CrossRef
45.
Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923PubMedCrossRef
46.
Sun M, Choueri T, Hamnvik O-P, Preston M, De Velasco G, Jiang W et al (2016) Comparison of Gonadotrophin-releasing hormone agonists and orchiectomy. JAMA Oncology 2(4):500–507PubMedCrossRef
47.
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL (2017) Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer: a population based study. J Urol 197(5):1251–1257PubMedCrossRef
48.
Beebe-Dimmer J, Cetin K, Shahinian V (2012) Timing of androgen deprivation therapy and fracture among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 21:70–78PubMedCrossRef
49.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators (2018) Apalutamide treatment and metastasis-free survival in prostate Cancer. N Engl J Med 378(15):1408–1418PubMedCrossRef
50.
Graff J, Baciarello G, Armstrong A, Higano C, Iversen PW, Flaig W et al (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27:286–294PubMedCrossRef
51.
Morote J, Gomez-Caamano J, Alvarez-Ossorio J, Pesqueira D, Tabernero A, Veiga F et al (2015) The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol 193(6):1963–1969PubMedCrossRef
52.
Smith M, Lee H, McGovern F, Fallon M, Goode M, Zeitman A (2008) Metabolic changes during gonadotrophin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 112:2188–2194PubMedPubMedCentralCrossRef
53.
Keating N, O'Malley J, Smith M (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456PubMedCrossRef
54.
Taylor L, C SE, Du X (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate. Cancer. 115(11):2388–2399PubMedCrossRef
55.
Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clinical Genitourinary Cancer 16(3):e645–ee53PubMedCrossRef
56.
Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY (2018) A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol 73(2):156–165PubMedCrossRef
57.
Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, Mucci LA, Lipsitz SR, Chun FK, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Trinh QD (2018) Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J Urol 200(3):573–581PubMedCrossRef
58.
National Institute for Health and Care Excellence (NICE). Clinical guideline [CG175] Managing adverse effects of hormone therapy UK: NICE; 2014 [updated January 2014
59.
Daly PE, Dunne MT, O'Shea CM, Finn MA, Armstrong JG (2012) The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4-versus 8-month randomised trial (Irish clinical oncology research group 97-01). Radiother Oncol 104(1):96–102PubMedCrossRef
60.
Jones C, Hunt D, McGowan D, Amin M, Chetner M, Bruner D et al (2011) Radiotherapy and short-term androgen deprivation therapy for localized prostate cancer. The New England Journal of Medicine 365(2)PubMedCrossRef
61.
Sharpley C (2007) Actual change in anxiety and depression among Australian men with prostate cancer. Journal of Men's Health and Gender 4(1):32–38CrossRef
62.
Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M, Jacobsen PB (2015) Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psycho-Oncology. 24(4):472–477PubMedCrossRef
63.
Himelhoch S, Weller W, Wu A, Anderson G, Cooper L (2004) Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care 42:512–521PubMedCrossRef
64.
Roviello G, Generali D (2018) Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. Med Oncol 35(3):29PubMedCrossRef
65.
Alibhai SM, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M et al (2015) Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer. 121(14):2350–2357PubMedCrossRef
66.
Gonzalez B, Jim H, Small B, Sutton S, Fishman M, Zachariah B, Heysek RV, Jacobsen PB (2016) Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24:2201–2207PubMedCrossRef
67.
Galvão D, Taaffe D, Spry N, Joseph D, Turner D, Newton R (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198–203PubMedCrossRef
68.
Hussain S, Breunis H, Timilshina N, Alibhai SMH (2010) Falls in men on androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology 1(1):32–39CrossRef
69.
Graff J, Baciarello G, Armstrong A, Higano C, Iversen P, Flaig T, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrate resistant prostate cancer: results from PREVAIL. Ann Oncol 27:286–294PubMedCrossRef
70.
Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M (2015) Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 33(9):1281–1289PubMedCrossRef
71.
Bourke L, Kirkbride P, Hooper R, Rosario A, Chico T, Rosario D (2013) Endocrine therapy in prostate cancer: time for reapprisal of risks, benefits and cost-effectiveness? Br J Cancer 108:9–13PubMedCrossRef
72.
Pearce A, Haas M, Viney R (2013) Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review. Applied Health Economics and Health Policy 11:619–637PubMedCrossRef
Metadata
Title
Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review
Authors
Kim Edmunds
Haitham Tuffaha
Daniel A Galvão
Paul Scuffham
Robert U Newton
Publication date
01-05-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05255-5

Other articles of this Issue 5/2020

Supportive Care in Cancer 5/2020 Go to the issue

Original Article

Late referral of cancer patients with malnutrition to dietitians: a prospective study of clinical practice

Original Article

Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer

Original Article

Gastrointestinal symptoms are associated with trajectories of chemotherapy-induced nausea

Letter to the Editor

Reply to Kohei Kajiwara, Jun Kako, Hiroko Noto, Yasufumi Oosono, and Masamitsu Kobayashi

Original Article

Knowledge matters and empowers: HPV vaccine advocacy among HPV-related cancer survivors

Original Article

Female cancer survivor perspectives on remote intervention components to support physical activity maintenance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits